Aspirin for primary prevention

BMJ

Volumn 321, Issue 7274, 2000, Pages 1472-

  Ramsay, Lawrence E ^a   Sanmuganathan, Philemon S ^a   Wallis, Erica J ^a   Jackson, Peter R ^a   Alkhenizan, Abdullah ^b  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

CLINICAL TRIAL; HUMAN; HYPERTENSION; NOTE; PRIMARY PREVENTION; THROMBOSIS;

ASPIRIN; CLINICAL TRIALS; HUMANS; HYPERTENSION; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; THROMBOSIS;

EID: 85007664405     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.321.7274.1472     Document Type: Letter

References (10)

1. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Prescribing aspirin safely for primary prevention of cardiovascular disease and the need for absolute cardiovascular risk estimation. Br J Clin Pharmacol 2000; 49: 498P(abstract).
2. Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999; 319: 630–635.
3. Meade TW, Brennan PJ on behalf of the MRC General Practice Research Framework. Determination of who may derive the most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ 2000; 321: 13–17. (1 July.)
4. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing physicians' health study. N Engl J Med 1989; 321: 129–135.
5. Kjeldsen SE, Kolloch RE, Leonetti G, Mallion J-M, Zanchetti A, et al for the HOT Study Group. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. J Hypertens 2000; 18: 629–642.
6. Meade TW, Brennan PJ on behalf of the MRC General Practice Research Framework. Determination of who may derive the most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ 2000; 321: 13–17. (1 July.)
7. Hanson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al for the HOT Study Group. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998; 351: 1755–1762.
8. Iso H, Hennekens CH, Stampfer MJ, Rexrode KM, Colditz GA, Speizer FE, et al. Prospective study of aspirin use and risk of stroke in women. Stroke 1999; 30: 1764–1771.
9. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 1998; 280: 1930–1935.
10. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomized controlled trials. Br J Clin Pharmacol 1993; 35: 219–226.